Investopedia: Will Immunotherapy Disrupt The Oncology Market?

Goldman Sachs' recent list of eight "disruptive technologies" included new therapies to fight cancer, drugs that promise to u...

Investopedia: Does Amgen Deserve To Be Part Of The Biotech Bull Run?

For as much as the sell-side seems to complain about Amgen (Nasdaq: AMGN ), it doesn't seem to have resulted in the company missing ou...

Investopedia: AstraZeneca Pays Up To Patch Up Another Key Area

Pascal Soriot is still hard at work in patching up AstraZeneca 's (NYSE: AZN ) battered pipeline and five-year profit prospects. Followi...

Investopedia: AstraZeneca Looks To Fish Oil To Round Out Its Cardio Portfolio

Investors waiting for M&A activity in the controversial purified pharma-grade fish oil market got some Tuesday morning, but probably n...

Seeking Alpha: No News Becoming Bad News For Lexicon Pharmaceuticals

Normally you would think that having a differentiated and proprietary diabetes compound with solid supporting data would make a biotech re...

Seeking Alpha: Alkermes Still Not Getting Full Credit For Its Pipeline

Biotech is a strange world, one where investors often seem to prefer stories that are relatively weak on sales, earnings, and actual data. ...